Abstract
The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing antibodies to the new species in humans is unclear. The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 IVIG preparations, produced from plasma collected in Europe and the US, highly potent neutralization of a seasonal coronavirus was confirmed, yet no cross-neutralization of the new SARS-CoV-2 was seen.
SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.
Competing Interest Statement
Authors are employees of Baxter AG, now part of the Takeda group of companies, Vienna, Austria. MK, CA, MRF and TRK have Takeda stock interest.
Footnotes
Potential conflicts of interest, Authors are employees of Baxter AG, now part of the Takeda group of companies, Vienna, Austria. MK, CA, MRF and TRK have Takeda stock interest.
Financial support, This study was funded by Baxter AG, now part of the Takeda group of companies, Vienna, Austria.
Presented in part, The results have not been presented anywhere else.